Takeda CEO says Japanese drugmaker back on track

Takeda Pharmaceutical has its work cut out. On the heels of a big earnings shortfall, the Japanese drugmaker's CEO is touting its cost-cutting programs and growth in emerging markets. Report

Suggested Articles

In previously untreated nonsquamous NSCLC, a Tyvyt-chemo combo beat chemo alone at stalling the time to tumor progression or death.

It’s been a big year for Bristol's Opdivo-Yervoy combo in lung cancer, but with new mesothelioma data in hand, the duo isn’t done making headlines.

A third spinal muscular atrophy treatment option is set to debut with the FDA’s approval for Roche’s Evrysdi, formerly known as risdiplam.